dr. francois nader, president and ceo, and find out what it means for his company going forward. dr. nader, welcome back to "mad money." >> thank you, jim. good to see you. >> first, congratulations. this was a real coup, and i think a lot of people were taken aback, because they know this drug has gigantic potential in europe, but you were able to get it back for just $50 million. >> well, absolutely thrilled with this deal. actually, we got back two products, worldwide, excellent opportunity for nps. >> why would they do that? to me, they've got a sales force, they see the numbers. wall street is talking about this being a multihundred million dollar deal for you guys. >> we hope so. but our focus is the rare diseases, orphan indication. this is our core business. it's not takeda's. >> right. they're mass and you're orphan, so to speak. >> in many ways, but at the same time, they share the up side, because the deal which was excellent for us, we did not pay cash, we paid in stock so they can benefit from the up side. >> now, this morning in the "new york times," a positive article a